SCHEMBL3109481

SCHEMBL3109481

FC(F)(F)c1ccccc1-c1nc(NCCNc2n[nH]c3ccccc23)c2ccccc2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 13/20 0.67
WDR48 Q8TAF3 13/20 0.67
CYP1A2 P05177 8/20 0.65
CYP3A4 P08684 7/20 0.65
CYP2C19 P33261 6/20 0.65
USP2 O75604 4/20 0.65
CLK4 Q9HAZ1 2/20 0.65
CYP2D6 P10635 7/20 0.64
TSHR P16473 3/20 0.64
RECQL P46063 1/20 0.59
ALOX15 P16050 1/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
PIP4K2C Q8TBX8 1/20 0.57
HSD17B10 Q99714 1/20 0.55
GLA P06280 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL786421 0.90 USP1 (0.64) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786464 0.81 USP1 (0.64) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786256 0.81 USP1 (0.64) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786232 0.80 CYP1A2 (0.62) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786427 0.80 USP1 (0.61) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL785772 0.80 USP1 (0.61) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL802148 0.80 CYP1A2 (0.59) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL13962744 0.80 USP1 (0.62) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786391 0.79 CYP1A2 (0.57) USP1WDR48CYP1A2CYP3A4CYP2C19
SCHEMBL786568 0.79 USP1 (0.62) USP1WDR48CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-1474147-B1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMA (US) 2010-05-05 EP disclosed
EP-1474147-B1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMA (US) 2010-05-05 EP disclosed
EP-1474147-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-11-10 EP disclosed
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors VERTEX PHARMACEUTICALS, INCORPORATED 2003-10-23 US disclosed
WO-2003049739-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors GSK3B, GSK3A, GSKIP USP1 4041/4885WDR48 1964/4885CYP1A2 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.